137.2K XNAS Volume
XNAS 25 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 20 Mar 2025 | 5,416 | 1,309,296 | - | 0.7 | 3,950 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.73 per share. | 20 Mar 2025 | 15,000 | 1,324,296 | - | 0.7 | 10,959 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Mar 2025 | 29,999 | 1,294,774 | - | 0.8 | 22,631 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.75 per share. | 14 Mar 2025 | 9,106 | 1,303,880 | - | 0.7 | 6,829 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.71 per share. | 12 Mar 2025 | 47,500 | 1,214,775 | - | 0.7 | 33,744 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.72 per share. | 12 Mar 2025 | 50,000 | 1,264,775 | - | 0.7 | 35,820 | Common Stock |
| Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Bryant D. Lim | CLO, CFO, Corp Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 200,000 | 200,000 | - | - | Employee Stock Option (right to buy) | |
| Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 496,000 | 496,000 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Andrew P. Combs | Chief Chemistry Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Feb 2025 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2025 | 9,375 | 72,716 | - | - | Common Stock | |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.39 per share. | 04 Jan 2025 | 3,859 | 68,857 | - | 1.4 | 5,364 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2025 | 9,375 | 46,875 | - | - | Restricted Stock Unit | |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 1.21 per share. | 31 Dec 2024 | 5,000 | 142,553 | - | 1.2 | 6,044 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 1.20 per share. | 30 Dec 2024 | 10,000 | 137,553 | - | 1.2 | 12,000 | Common Stock |
| Andrew P. Combs | Chief Chemistry Officer | Purchase of securities on an exchange or from another person at price $ 1.37 per share. | 20 Dec 2024 | 60,000 | 377,623 | - | 1.4 | 82,002 | Common Stock |
| Andrew P. Combs | Chief Chemistry Officer | Purchase of securities on an exchange or from another person at price $ 1.15 per share. | 20 Dec 2024 | 3,075 | 317,623 | - | 1.1 | 3,536 | Common Stock |
| Bryant Lim D. | CLO, Interim CFO, Corp Sec. | Purchase of securities on an exchange or from another person at price $ 0.91 per share. | 19 Dec 2024 | 25,000 | 27,400 | - | 0.9 | 22,638 | Common Stock |
| Vaddi Krishna | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.89 per share. | 18 Dec 2024 | 6,888 | 127,553 | - | 0.9 | 6,116 | Common Stock |
| Vaddi Krishna | Director, CEO | Purchase of securities on an exchange or from another person at price $ 0.93 per share. | 18 Dec 2024 | 100,000 | 1,167,275 | - | 0.9 | 93,210 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 9,375 | 66,690 | - | - | Common Stock | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Oct 2024 | 9,375 | 56,250 | - | - | Restricted Stock Unit | |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.00 per share. | 04 Oct 2024 | 3,349 | 63,341 | - | 2 | 6,698 | Common Stock |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.60 per share. | 04 Jul 2024 | 3,347 | 57,315 | - | 3.6 | 12,049 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2024 | 9,375 | 60,662 | - | - | Common Stock | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2024 | 9,375 | 65,625 | - | - | Restricted Stock Unit | |
| Martin Babler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| David P. Bonita | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Mardi C. Dier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Bryant D. Lim | CLO, Interim CFO, Corp Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2024 | 25,000 | 25,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,375 | 54,634 | - | - | Common Stock | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2024 | 9,375 | 75,000 | - | - | Restricted Stock Unit | |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.74 per share. | 04 Apr 2024 | 3,347 | 51,287 | - | 4.7 | 15,865 | Common Stock |
| Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 175,000 | 175,000 | - | - | Employee Stock Option (right to buy) | |
| Bryant D. Lim | Chief Legal Officer, Corp Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 425,000 | 425,000 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Andrew P. Combs | Chief Chemistry Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 3.77 per share. | 04 Jan 2024 | 3,844 | 45,259 | - | 3.8 | 14,492 | Common Stock |
| Huang Jane | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2024 | 9,375 | 84,375 | - | - | Restricted Stock Unit | |
| Huang Jane | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jan 2024 | 9,375 | 49,103 | - | - | Common Stock | |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2023 | 9,375 | 103,125 | - | - | Restricted Stock Unit | |
| Jane Huang | President, CMO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.65 per share. | 04 Jul 2023 | 3,242 | 30,353 | - | 4.6 | 15,075 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Jul 2023 | 9,375 | 33,595 | - | - | Common Stock | |
| Martin Babler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| David P. Bonita | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Mardi C. Dier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2023 | 23,500 | 23,500 | - | - | Director Stock Option (Right to Buy) | |
| Bryant D. Lim | Chief Legal Officer, Corp Sec. | Purchase of securities on an exchange or from another person at price $ 5.39 per share. | 24 May 2023 | 2,400 | 2,400 | - | 5.4 | 12,936 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.01 per share. | 24 May 2023 | 1,000 | 1,066,375 | - | 5.0 | 5,011 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.31 per share. | 24 May 2023 | 900 | 1,067,275 | - | 5.3 | 4,779 | Common Stock |
| Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 5.50 per share. | 23 May 2023 | 5,000 | 42,165 | - | 5.5 | 27,500 | Common Stock |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.63 per share. | 23 May 2023 | 11,856 | 1,065,375 | - | 5.6 | 66,749 | Common Stock |
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 5.75 per share. | 22 May 2023 | 869,565 | 10,119,756 | - | 5.8 | 4,999,999 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2023 | 37,500 | 112,500 | - | - | Restricted Stock Unit | |
| Jane Huang | President, CMO | Sale of securities on an exchange or to another person at price $ 6.12 per share. | 04 Apr 2023 | 13,280 | 24,220 | - | 6.1 | 81,274 | Common Stock |
| Jane Huang | President, CMO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2023 | 37,500 | 37,500 | - | - | Common Stock | |
| Bryant D. Lim | Chief Legal Officer, Corp Sec. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 250,000 | 250,000 | - | - | Employee Stock Option (Right to Buy) | |
| Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 330,000 | 330,000 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Andrew P. Combs | EVP, Head of Chemistry | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2023 | 135,000 | 135,000 | - | - | Employee Stock Option (right to buy) | |
| Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Dec 2022 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Krishna Vaddi | Director, CEO | Purchase of securities on an exchange or from another person at price $ 5.13 per share. | 20 Dec 2022 | 19,188 | 120,665 | - | 5.1 | 98,446 | Common Stock |
| Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.76 per share. | 08 Dec 2022 | 10,000 | 35,873 | - | 4.8 | 47,600 | Common Stock |
| Martin Babler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 31,293 | 31,293 | - | - | Director Stock Option (Right to Buy) | |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| David P. Bonita | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| Mardi C. Dier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2022 | 34,300 | 34,300 | - | - | Director Stock Option (Right to Buy) | |
| Laurent Chardonnet | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.23 per share. | 01 Jun 2022 | 10,000 | 24,500 | - | 4.2 | 42,300 | Common Stock |
| Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 460,000 | 460,000 | - | - | Employee Stock Option (Right to Buy) | |
| Jane Huang | President, CMO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 150,000 | 150,000 | - | - | Restricted Stock Unit | |
| Andrew P. Combs | EVP, Head of Chemistry | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 31 Mar 2022 | 36,062 | 304,442 | - | 1.9 | 68,157 | Common Stock |
| Andrew P. Combs | EVP, Head of Chemistry | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 36,062 | 50,397 | - | - | Employee Stock Option (right to buy) | |
| Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 7.51 per share. | 21 Mar 2022 | 6,500 | 14,500 | - | 7.5 | 48,815 | Common Stock |
| Laurent Chardonnet | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Krishna Vaddi | Director, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 327,900 | 327,900 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Andrew P. Combs | EVP, Head of Chemistry | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 100,000 | 100,000 | - | - | Employee Stock Option (right to buy) | |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2022 | 90,000 | 90,000 | - | - | Employee Stock Option (right to buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 11,206 | 11,206 | - | - | Director Stock Option (Right to Buy) | |
| Krishna Vaddi | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 12.13 per share. | 13 Dec 2021 | 8,000 | 1,053,519 | - | 12.1 | 97,035 | Common Stock |
| Andrew P. Combs | EVP, Head of Chemistry | Purchase of securities on an exchange or from another person at price $ 11.60 per share. | 13 Dec 2021 | 4,000 | 268,380 | - | 11.6 | 46,400 | Common Stock |
| Andrew P. Combs | EVP, Head of Chemistry | Purchase of securities on an exchange or from another person at price $ 12.12 per share. | 13 Dec 2021 | 4,000 | 264,380 | - | 12.1 | 48,480 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.85 per share. | 16 Nov 2021 | 28,751 | 29,195 | - | 12.8 | 369,450 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Nov 2021 | 28,751 | 196,045 | - | - | Employee Stock Option (right to buy) | |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Sale of securities on an exchange or to another person at price $ 16.42 per share. | 16 Nov 2021 | 400 | 444 | - | 16.4 | 6,570 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Sale of securities on an exchange or to another person at price $ 15.87 per share. | 16 Nov 2021 | 28,351 | 844 | - | 15.9 | 449,962 | Common Stock |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2021 | 8,022 | 8,022 | - | - | Director Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.26 per share. | 05 Oct 2021 | 5,908 | 9,092 | - | 30.3 | 178,762 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Oct 2021 | 15,000 | 137,610 | - | - | Employee Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.06 per share. | 05 Oct 2021 | 1,289 | 0 | - | 32.1 | 41,330 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.30 per share. | 05 Oct 2021 | 7,803 | 1,289 | - | 31.3 | 244,257 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 05 Oct 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.91 per share. | 07 Sep 2021 | 7,487 | 7,513 | - | 35.9 | 268,867 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2021 | 15,000 | 167,610 | - | - | Employee Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.79 per share. | 07 Sep 2021 | 4,640 | 0 | - | 37.8 | 175,334 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.92 per share. | 07 Sep 2021 | 2,873 | 4,640 | - | 36.9 | 106,081 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 07 Sep 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.29 per share. | 02 Sep 2021 | 3,343 | 17,407 | - | 40.3 | 134,697 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2021 | 17,000 | 207,796 | - | - | Employee Stock Option (right to buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 42.50 per share. | 02 Sep 2021 | 6,930 | 3,750 | - | 42.5 | 294,507 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 41.52 per share. | 02 Sep 2021 | 6,727 | 10,680 | - | 41.5 | 279,289 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.85 per share. | 02 Sep 2021 | 17,000 | 20,750 | - | 12.9 | 218,450 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.19 per share. | 26 Aug 2021 | 1,700 | 172,920 | - | 35.2 | 59,819 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 6,014 | 27,018 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Aug 2021 | 1,700 | 33,032 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.08 per share. | 26 Aug 2021 | 607 | 172,920 | - | 37.1 | 22,505 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.23 per share. | 26 Aug 2021 | 2,707 | 173,527 | - | 36.2 | 98,085 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.32 per share. | 26 Aug 2021 | 2,700 | 176,234 | - | 35.3 | 95,377 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 26 Aug 2021 | 6,014 | 178,934 | - | 1.4 | 8,600 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 26 Aug 2021 | 1,700 | 174,620 | - | 1.4 | 2,431 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 1,728 | 34,732 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2021 | 558 | 42,672 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.07 per share. | 13 Aug 2021 | 2,286 | 172,920 | - | 35.1 | 80,161 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 13 Aug 2021 | 1,728 | 175,206 | - | 1.4 | 2,471 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 13 Aug 2021 | 558 | 173,478 | - | 1.9 | 1,055 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 05 Aug 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 29.93 per share. | 05 Aug 2021 | 6,116 | 8,884 | - | 29.9 | 183,070 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 Aug 2021 | 15,000 | 167,610 | - | - | Employee Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.63 per share. | 05 Aug 2021 | 100 | 0 | - | 32.6 | 3,263 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.15 per share. | 05 Aug 2021 | 6,721 | 100 | - | 32.1 | 216,051 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.03 per share. | 05 Aug 2021 | 2,063 | 6,821 | - | 31.0 | 64,010 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 35.45 per share. | 27 Jul 2021 | 19,320 | 173,600 | - | 35.4 | 684,840 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jul 2021 | 20,000 | 36,460 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.09 per share. | 27 Jul 2021 | 680 | 172,920 | - | 36.1 | 24,540 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 27 Jul 2021 | 20,000 | 192,920 | - | 1.4 | 28,600 | Common Stock |
| David J. Mauro | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 95,000 | 95,000 | - | - | Employee Stock Option (Right to Buy) | |
| Brian D. Piper | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 115,650 | 115,650 | - | - | Employee Stock Option (Right to Buy) | |
| Krishna Vaddi | Director, President, CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 285,800 | 285,800 | - | - | Employee Stock Option (Right to Buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 95,000 | 95,000 | - | - | Employee Stock Option (Right to Buy) | |
| Andrew P. Combs | EVP, Head of Chemistry | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 95,000 | 95,000 | - | - | Employee Stock Option (Right to Buy) | |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Jul 2021 | 85,000 | 85,000 | - | - | Employee Stock Option (Right to Buy) | |
| Martin Babler | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2021 | 36,400 | 36,400 | - | - | Employee Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 27.17 per share. | 06 Jul 2021 | 10,445 | 4,555 | - | 27.2 | 283,743 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2021 | 15,000 | 182,610 | - | - | Employee Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.84 per share. | 06 Jul 2021 | 300 | 0 | - | 28.8 | 8,653 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 28.13 per share. | 06 Jul 2021 | 4,255 | 300 | - | 28.1 | 119,711 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 06 Jul 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| Paul A. Friedman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| David P. Bonita | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| Mardi C. Dier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jun 2021 | 23,344 | 23,344 | - | - | Director Stock Option (Right to Buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 32.73 per share. | 07 Jun 2021 | 12,700 | 0 | - | 32.7 | 415,665 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 07 Jun 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.35 per share. | 07 Jun 2021 | 1,400 | 13,600 | - | 30.4 | 42,496 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.62 per share. | 07 Jun 2021 | 900 | 12,700 | - | 31.6 | 28,462 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Jun 2021 | 15,000 | 197,610 | - | - | Common Stock | |
| Brian D. Piper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 33.53 per share. | 25 May 2021 | 3,110 | 5,223 | - | 33.5 | 104,263 | Common Stock |
| Brian D. Piper | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 25 May 2021 | 8,333 | 8,333 | - | 1.9 | 15,749 | Common Stock |
| Brian D. Piper | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 May 2021 | 8,333 | 272,662 | - | - | Employee Stock Option (Right to Buy) | |
| Brian D. Piper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 36.09 per share. | 25 May 2021 | 399 | 0 | - | 36.1 | 14,401 | Common Stock |
| Brian D. Piper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 35.45 per share. | 25 May 2021 | 1,736 | 399 | - | 35.4 | 61,536 | Common Stock |
| Brian D. Piper | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 34.11 per share. | 25 May 2021 | 3,088 | 2,135 | - | 34.1 | 105,338 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.43 per share. | 07 May 2021 | 10,000 | 182,920 | - | 1.4 | 14,300 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2021 | 10,000 | 56,460 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.85 per share. | 07 May 2021 | 200 | 172,920 | - | 41.9 | 8,370 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 41.14 per share. | 07 May 2021 | 5,836 | 173,120 | - | 41.1 | 240,090 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.30 per share. | 07 May 2021 | 3,964 | 178,956 | - | 40.3 | 159,732 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.36 per share. | 05 May 2021 | 3,415 | 11,585 | - | 39.4 | 134,399 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 05 May 2021 | 15,000 | 212,610 | - | - | Common Stock | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 41.07 per share. | 05 May 2021 | 1,109 | 0 | - | 41.1 | 45,545 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 40.30 per share. | 05 May 2021 | 10,476 | 1,109 | - | 40.3 | 422,148 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 05 May 2021 | 15,000 | 15,000 | - | 1.9 | 28,350 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Sale of securities on an exchange or to another person at price $ 40.29 per share. | 29 Apr 2021 | 3,223 | 444 | - | 40.3 | 129,853 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 3,223 | 4,323 | - | - | Employee Stock Option (right to buy) | |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 29 Apr 2021 | 3,223 | 3,667 | - | 1.9 | 6,091 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.29 per share. | 29 Apr 2021 | 3,295 | 3,750 | - | 40.3 | 132,765 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Apr 2021 | 3,295 | 4,323 | - | - | Employee Stock Option (right to buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 29 Apr 2021 | 3,295 | 7,045 | - | 1.9 | 6,228 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 34.66 per share. | 27 Apr 2021 | 7,688 | 17,312 | - | 34.7 | 266,478 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Apr 2021 | 25,000 | 227,610 | - | - | Employee Stock Option (right to buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 36.11 per share. | 27 Apr 2021 | 1,711 | 0 | - | 36.1 | 61,791 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 35.68 per share. | 27 Apr 2021 | 15,601 | 1,711 | - | 35.7 | 556,580 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 27 Apr 2021 | 25,000 | 25,000 | - | 1.9 | 47,250 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 30.82 per share. | 19 Apr 2021 | 21,000 | 4,000 | - | 30.8 | 647,273 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Apr 2021 | 25,000 | 252,610 | - | - | Employee Stock Option (right to buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 31.27 per share. | 19 Apr 2021 | 4,000 | 0 | - | 31.3 | 125,077 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 19 Apr 2021 | 25,000 | 25,000 | - | 1.9 | 47,250 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 9,617 | 277,610 | - | - | Employee Stock Option (right to buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.04 per share. | 08 Apr 2021 | 3,274 | 6,343 | - | 37.0 | 121,256 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 37.83 per share. | 08 Apr 2021 | 1,501 | 4,842 | - | 37.8 | 56,780 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.00 per share. | 08 Apr 2021 | 1,293 | 3,549 | - | 39.0 | 50,423 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.56 per share. | 08 Apr 2021 | 3,549 | 0 | - | 39.6 | 140,393 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 08 Apr 2021 | 9,617 | 9,617 | - | 1.9 | 18,176 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 4,630 | 66,460 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.57 per share. | 08 Apr 2021 | 1,669 | 172,920 | - | 39.6 | 66,040 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 38.97 per share. | 08 Apr 2021 | 669 | 174,589 | - | 39.0 | 26,073 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 37.72 per share. | 08 Apr 2021 | 875 | 175,258 | - | 37.7 | 33,003 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 36.97 per share. | 08 Apr 2021 | 1,417 | 176,133 | - | 37.0 | 52,387 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 08 Apr 2021 | 4,630 | 177,550 | - | 1.4 | 6,621 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 08 Apr 2021 | 100 | 544 | - | 1.9 | 189 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Apr 2021 | 100 | 444 | - | 40 | 4,000 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 100 | 7,546 | - | - | Employee Stock Option (right to buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 08 Apr 2021 | 200 | 3,950 | - | 1.9 | 378 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.00 per share. | 08 Apr 2021 | 200 | 3,750 | - | 40 | 8,000 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Apr 2021 | 200 | 7,618 | - | - | Employee Stock Option (right to buy) | |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 07 Apr 2021 | 15,383 | 15,383 | - | 1.9 | 29,074 | Common Stock |
| David J. Mauro | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 15,383 | 287,227 | - | - | Employee Stock Option (right to buy) | |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.69 per share. | 07 Apr 2021 | 7,083 | 0 | - | 39.7 | 281,116 | Common Stock |
| David J. Mauro | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 39.03 per share. | 07 Apr 2021 | 8,300 | 7,083 | - | 39.0 | 323,908 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.02 per share. | 07 Apr 2021 | 8,289 | 180,001 | - | 39.0 | 323,405 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 1.43 per share. | 07 Apr 2021 | 15,370 | 188,290 | - | 1.4 | 21,979 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 15,370 | 71,090 | - | - | Employee Stock Option (right to buy) | |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 40.30 per share. | 07 Apr 2021 | 200 | 172,920 | - | 40.3 | 8,060 | Common Stock |
| Peggy A. Scherle | Chief Scientific Officer | Sale of securities on an exchange or to another person at price $ 39.63 per share. | 07 Apr 2021 | 6,881 | 173,120 | - | 39.6 | 272,679 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Sale of securities on an exchange or to another person at price $ 40.04 per share. | 07 Apr 2021 | 1,000 | 444 | - | 40.0 | 40,043 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.89 per share. | 07 Apr 2021 | 1,000 | 1,444 | - | 1.9 | 1,890 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 1,000 | 7,646 | - | - | Employee Stock Option (right to buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Grant, award, or other acquisition of securities at price $ 1.89 per share. | 07 Apr 2021 | 828 | 4,578 | - | 1.9 | 1,565 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Apr 2021 | 828 | 7,818 | - | - | Employee Stock Option (right to buy) | |
| Christopher Pierce | EVP and Chief of Business Oper | Sale of securities on an exchange or to another person at price $ 40.08 per share. | 07 Apr 2021 | 828 | 3,750 | - | 40.1 | 33,188 | Common Stock |
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 11 Jan 2021 | 41,700 | 5,596,886 | - | - | Non-Voting Common Stock | |
| Mardi C. Dier | Director | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 29 Sep 2020 | 10,000 | 10,000 | - | 19 | 190,000 | Common Stock |
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 101,477 | 101,477 | - | - | Common Stock | ||
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 0 | - | - | Series A Preferred Stock | ||
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 0 | - | - | Series A Preferred Stock | ||
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 101,477 | 0 | - | - | Series A Preferred Stock | ||
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 551,774 | - | - | Common Stock | ||
| Krishna Vaddi | Director, President, CEO | 29 Sep 2020 | 32,876 | 551,776 | - | - | Common Stock | ||
| Andrew P. Combs | EVP, Head of Chemistry | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 29 Sep 2020 | 1,000 | 260,380 | - | 19 | 19,000 | Common Stock |
| Deborah Morosini | EVP, Chief of Clinical Affairs | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 29 Sep 2020 | 444 | 444 | - | 19 | 8,436 | Common Stock |
| Christopher Pierce | EVP and Chief of Business Oper | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 29 Sep 2020 | 3,750 | 3,750 | - | 19 | 71,250 | Common Stock |
| Mardi C. Dier | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 3,458 | 3,458 | - | - | Director Stock Option (right to buy) | |
| Victor Sandor | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 Sep 2020 | 3,458 | 3,458 | - | - | Director Stock Option (right to buy) | |
| Paul A. Friedman | Director | 27 Mar 2020 | 295,794 | 0 | - | - | Series A Preferred Stock | ||
| Paul A. Friedman | Director | 27 Mar 2020 | 152,576 | 0 | - | - | Series B Preferred Stock | ||
| Paul A. Friedman | Director | 27 Mar 2020 | 295,794 | 347,522 | - | - | Common Stock | ||
| Paul A. Friedman | Director | 27 Mar 2020 | 152,576 | 500,098 | - | - | Common Stock | ||
| Paul A. Friedman | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 Mar 2020 | 76,288 | 152,576 | - | - | Series B Preferred Stock | |
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 619,850 | 0 | - | - | Series C Preferred Stock | ||
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 413,234 | 0 | - | - | Series C Preferred Stock | ||
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 5,555,186 | 5,555,186 | - | - | Non-Voting Common Stock | ||
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 27 Mar 2020 | 526,300 | 526,300 | - | 19 | 9,999,700 | Common Stock |
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 19.00 per share. | 27 Mar 2020 | 710,500 | 917,412 | - | 19 | 13,499,500 | Common Stock |
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 8,332,779 | 9,250,191 | - | - | Common Stock | ||
| David P. Bonita | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Mar 2020 | 46,688 | 46,688 | - | - | Director Stock Option (right to buy) | |
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 Mar 2020 | 3,681,822 | 7,363,644 | - | - | Series B Preferred Stock | |
| David P. Bonita | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 27 Mar 2020 | 1,033,084 | 1,033,084 | - | - | Series C Preferred Stock | |
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 3,294,743 | 0 | - | - | Series A Preferred Stock | ||
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 2,196,494 | 0 | - | - | Series A Preferred Stock | ||
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 4,418,186 | 0 | - | - | Series B Preferred Stock | ||
| David P. Bonita | Director, Ten Percent Owner | 27 Mar 2020 | 2,945,458 | 0 | - | - | Series B Preferred Stock |